The Transfusion-dependent thalassaemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Transfusion-dependent thalassaemia market dynamics.
DelveInsight’s “Transfusion-dependent thalassaemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Transfusion-dependent thalassaemia, historical and forecasted epidemiology as well as the Transfusion-dependent thalassaemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Transfusion-dependent thalassaemia Market Report:
- The Transfusion-dependent thalassaemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Secondary iron overload is the main issue with Transfusion-dependent thalassaemia; if handled, it can cause damage to target organs and even death
- Transfusion-dependent thalassaemia prevalence is rare in the United States
- The prevalence of symptomatic cases of Transfusion-dependent thalassaemia estimates to be approximately 1 in 100,000 individuals in the general population
- Key Transfusion-dependent thalassaemia Companies: Celgene, bluebird bio, Sangamo Therapeutics, Protagonist Therapeutics, Novartis Pharmaceuticals, Vertex Pharmaceuticals, and others
- Key Transfusion-dependent thalassaemia Therapies: PTG-300, BIVV003, Mitapivat, Deferasirox, Luspatercept, sofosbuvir/velpatasvir, Deferasirox dispersable tablet, and others
- Transfusion dependence happens when a patient needs an average of more than 2 units of blood transfused every 28 days for at least three months
Request a sample for the Transfusion-dependent thalassaemia Market Report
Key benefits of the Transfusion-dependent thalassaemia Market report:
- Transfusion-dependent thalassaemia market report covers a descriptive overview and comprehensive insight of the Transfusion-dependent thalassaemia Epidemiology and Transfusion-dependent thalassaemia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Transfusion-dependent thalassaemia market report provides insights on the current and emerging therapies.
- Transfusion-dependent thalassaemia market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Transfusion-dependent thalassaemia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Transfusion-dependent thalassaemia market.
Discover more about therapies set to grab major Transfusion-dependent thalassaemia market share @ Transfusion-dependent thalassaemia market forecast
Transfusion-dependent thalassaemia Overview
According to the severity of the phenotype, which is brought on by a wide range of mutations in a homozygous or compound heterozygous state, -thalassemias can be categorised clinically as transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT).
Reduced synthesis of the -globin chain, which causes a /-chain imbalance, the precipitation of -globin-heme complexes, and poor erythropoiesis are the hallmarks of -thalassemias. The disease's hallmarks—ineffective erythropoiesis, persistent hemolytic anaemia, and compensatory hematopoietic expansion—are connected to how severe the chain unbalance is. Numerous clinical variants of beta-thalassemia, such as haemoglobin E/beta-thalassemia, which results from beta-thalassemia coinheritance with haemoglobin E, have been reported.
Transfusion-dependent thalassaemia Symptoms
The Transfusion-dependent thalassaemia symptoms include -
- Body Fatigue
- Weakness
- Shortness of breathing
- Dizziness
- Headaches
- Nausea and vomiting
Transfusion-dependent thalassaemia Epidemiology Segmentation:
The Transfusion-dependent thalassaemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Transfusion-dependent thalassaemia
- Prevalent Cases of Transfusion-dependent thalassaemia by severity
- Gender-specific Prevalence of Transfusion-dependent thalassaemia
- Diagnosed Cases of Episodic and Chronic Transfusion-dependent thalassaemia
Transfusion-dependent thalassaemia Market
The dynamics of the Transfusion-dependent thalassaemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Mitapivat, Deferasirox, and others during the forecasted period 2019-2032.
Download the report to understand which factors are driving Transfusion-dependent thalassaemia epidemiology trends @ Transfusion-dependent thalassaemia Epidemiological Insights
Transfusion-dependent thalassaemia Therapies
- PTG-300
- BIVV003
- Mitapivat
- Deferasirox
- Luspatercept
- sofosbuvir/velpatasvir
- Deferasirox dispersable tablet
Transfusion-dependent thalassaemia Key Companies
- Celgene
- bluebird bio
- Sangamo Therapeutics
- Protagonist Therapeutics
- Novartis Pharmaceuticals
- Vertex Pharmaceuticals
Scope of the Transfusion-dependent thalassaemia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Transfusion-dependent thalassaemia Companies: Celgene, bluebird bio, Sangamo Therapeutics, Protagonist Therapeutics, Novartis Pharmaceuticals, Vertex Pharmaceuticals, and others
- Key Transfusion-dependent thalassaemia Therapies: PTG-300, BIVV003, Mitapivat, Deferasirox, Luspatercept, sofosbuvir/velpatasvir, Deferasirox dispersable tablet, and others
- Therapeutic Assessment: Transfusion-dependent thalassaemia current marketed and Transfusion-dependent thalassaemia emerging therapies
- Migraine Market Dynamics: Transfusion-dependent thalassaemia market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Transfusion-dependent thalassaemia Market Access and Reimbursement
Table of Contents
1. Transfusion-dependent thalassaemia Market Report Introduction
2. Executive Summary for Transfusion-dependent thalassaemia
3. SWOT analysis of Transfusion-dependent thalassaemia
4. Transfusion-dependent thalassaemia Patient Share (%) Overview at a Glance
5. Transfusion-dependent thalassaemia Market Overview at a Glance
6. Transfusion-dependent thalassaemia Disease Background and Overview
7. Transfusion-dependent thalassaemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Transfusion-dependent thalassaemia
9. Transfusion-dependent thalassaemia Current Treatment and Medical Practices
10. Transfusion-dependent thalassaemia Unmet Needs
11. Transfusion-dependent thalassaemia Emerging Therapies
12. Transfusion-dependent thalassaemia Market Outlook
13. Country-Wise Transfusion-dependent thalassaemia Market Analysis (2019–2032)
14. Transfusion-dependent thalassaemia Market Access and Reimbursement of Therapies
15. Transfusion-dependent thalassaemia Market drivers
16. Transfusion-dependent thalassaemia Market barriers
17. Transfusion-dependent thalassaemia Appendix
18. Transfusion-dependent thalassaemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Transfusion-dependent thalassaemia treatment, visit @ Transfusion-dependent thalassaemia Medications
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com
